SMART MONEY GROUP

[Buyfor1sell for2]

AIM 8k On July 1, 2020, we entered into a material transfer and research agreement with the Japanese National Institute of Infectious Diseases (“NIID”) and Shionogi & Co., Ltd. (“Shionogi”) to test our drug Ampligen as a potential adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. Under the agreement, we will provide Ampligen samples for various research projects. The details of all preclinical and clinical results will remain confidential until released by NIID and Shionogi.